$96MSeries C, 7 October 2025
Funds the TORL-1-23 pivotal Phase 2 and confirmatory Phase 3 programs. Investor names not disclosed in sources found.
- Amount
- $96M
- Stage
- Series C
- Announced
- 7 October 2025
- Use of funds
- Funds the TORL-1-23 pivotal Phase 2 and confirmatory Phase 3 programs. Investor names not disclosed in sources found.
- Checked
- Amount and date matched across 3 press sources
- Sources
- TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 T pharmaceuticalonline.com
TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 T news.google.com
TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 T news.crunchbase.com